| A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects (NCT03288740) | Novo Nordisk A/S | 2017-09-21 |
| Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes (NCT03268005) | Novo Nordisk A/S | 2017-09-19 |
| Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) (NCT03061214) | Novo Nordisk A/S | 2017-08-28 |
| Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function. (NCT03212131) | Novo Nordisk A/S | 2017-08-16 |
| A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors (NCT03196297) | Novo Nordisk A/S | 2017-08-16 |
| Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India (NCT03070704) | Novo Nordisk A/S | 2017-08-16 |
| A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors (NCT03196284) | Novo Nordisk A/S | 2017-08-10 |
| Awareness, Care and Treatment in Obesity Management (NCT03235102) | Novo Nordisk A/S | 2017-08-03 |
| A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes (NCT03215498) | Novo Nordisk A/S | 2017-07-03 |
| Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes (NCT03191396) | Novo Nordisk A/S | 2017-06-27 |
| Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function (NCT03186495) | Novo Nordisk A/S | 2017-06-20 |
| A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD) (NCT03175120) | Novo Nordisk A/S | 2017-05-26 |
| A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) (NCT03172494) | Novo Nordisk A/S | 2017-05-26 |
| Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity (NCT03095807) | Novo Nordisk A/S | 2017-03-20 |
| Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus (NCT03086330) | Novo Nordisk A/S | 2017-03-15 |
| Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes (NCT03136484) | Novo Nordisk A/S | 2017-03-15 |
| A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs (NCT03078478) | Novo Nordisk A/S | 2017-03-13 |
| A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B (NCT03075670) | Novo Nordisk A/S | 2017-03-07 |
| LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors. (NCT02964247) | Novo Nordisk A/S | 2017-03-03 |
| A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency (NCT03075644) | Novo Nordisk A/S | 2017-03-03 |
| Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting (NCT02963935) | Novo Nordisk A/S | 2017-02-06 |
| Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin (NCT02963922) | Novo Nordisk A/S | 2017-02-06 |
| Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin (NCT03021187) | Novo Nordisk A/S | 2017-02-02 |
| Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A (NCT02994407) | Novo Nordisk A/S | 2017-01-30 |
| A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes (NCT02692716) | Novo Nordisk A/S | 2017-01-17 |
| Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes (NCT03018028) | Novo Nordisk A/S | 2017-01-10 |
| Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes (NCT03015220) | Novo Nordisk A/S | 2017-01-10 |
| First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity (NCT03015207) | Novo Nordisk A/S | 2017-01-06 |
| A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects (NCT03010475) | Novo Nordisk A/S | 2017-01-05 |
| In-market Utilisation of Liraglutide Used for Weight Management in Europe (NCT02967757) | Novo Nordisk A/S | 2016-12-22 |
| Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (NCT02938585) | Novo Nordisk A/S | 2016-12-12 |
| Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis. (NCT02970942) | Novo Nordisk A/S | 2016-11-30 |
| A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes (NCT02964104) | Novo Nordisk A/S | 2016-11-15 |
| Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight (NCT02958085) | Novo Nordisk A/S | 2016-11-04 |
| A Trial Investigating the Absorption, Metabolism and Excretion of Somapacitan After Single Dosing in Healthy Male Subjects (NCT02962440) | Novo Nordisk A/S | 2016-11-01 |
| A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus (NCT02938572) | Novo Nordisk A/S | 2016-10-19 |
| A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus (NCT02933853) | Novo Nordisk A/S | 2016-10-14 |
| Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A (NCT02941354) | Novo Nordisk A/S | 2016-10-10 |
| A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects. (NCT02920385) | Novo Nordisk A/S | 2016-10-10 |
| A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity. (NCT02941042) | Novo Nordisk A/S | 2016-10-10 |
| A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A (NCT02920398) | Novo Nordisk A/S | 2016-10-04 |
| Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity (NCT02918279) | Novo Nordisk A/S | 2016-09-29 |
| A Thorough QTc Trial Evaluating the Effect of SNAC on Cardiac Repolarisation in Healthy Male Subjects. (NCT02911870) | Novo Nordisk A/S | 2016-09-23 |
| A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs (NCT02911948) | Novo Nordisk A/S | 2016-09-21 |
| A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification (NCT02906917) | Novo Nordisk A/S | 2016-09-20 |
| Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only (NCT02906930) | Novo Nordisk A/S | 2016-09-20 |
| Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment (NCT02827708) | Novo Nordisk A/S | 2016-09-20 |
| Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. (NCT02849080) | Novo Nordisk A/S | 2016-09-20 |
| Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001 (NCT02868229) | Novo Nordisk A/S | 2016-09-12 |
| Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes. (NCT02877355) | Novo Nordisk A/S | 2016-08-22 |
| Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity (NCT02870231) | Novo Nordisk A/S | 2016-08-18 |
| Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus (NCT02863328) | Novo Nordisk A/S | 2016-08-10 |
| Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus (NCT02863419) | Novo Nordisk A/S | 2016-08-10 |
| A Trial Investigating the Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart in Healthy Chinese Subjects (NCT02844790) | Novo Nordisk A/S | 2016-07-26 |
| A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity (NCT02835235) | Novo Nordisk A/S | 2016-07-26 |
| Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes (NCT02825251) | Novo Nordisk A/S | 2016-07-06 |
| Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg® (NCT02821052) | Novo Nordisk A/S | 2016-07-01 |
| A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females (NCT02845219) | Novo Nordisk A/S | 2016-07-01 |
| A Study to Evaluate Safety and Effectiveness in Patients of All Age Groups Excluding Less Than 12 Months Old Infants With Diabetes Mellitus in Routine Clinical Practice in Korea (NCT02779413) | Novo Nordisk A/S | 2016-06-02 |
| A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes (NCT02773381) | Novo Nordisk A/S | 2016-06-02 |
| A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus (NCT02773368) | Novo Nordisk A/S | 2016-05-23 |
| Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients (NCT02773355) | Novo Nordisk A/S | 2016-05-16 |
| Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes (NCT02500706) | Novo Nordisk A/S | 2016-05-04 |
| Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes (NCT02670915) | Novo Nordisk A/S | 2016-05-04 |
| Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes (NCT02762578) | Novo Nordisk A/S | 2016-05-03 |
| A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus (NCT02754817) | Novo Nordisk A/S | 2016-04-26 |
| Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency (NCT02616562) | Novo Nordisk A/S | 2016-03-31 |
| Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes (NCT02730377) | Novo Nordisk A/S | 2016-03-28 |
| A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects. (NCT02717858) | Novo Nordisk A/S | 2016-03-16 |
| A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan (NCT02670213) | Novo Nordisk A/S | 2016-03-16 |
| A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years (NCT02696148) | Novo Nordisk A/S | 2016-03-14 |
| Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes (NCT02607865) | Novo Nordisk A/S | 2016-02-15 |
| A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus (NCT02501161) | Novo Nordisk A/S | 2016-01-31 |
| Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. (NCT02648204) | Novo Nordisk A/S | 2016-01-06 |
| Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan (NCT02648217) | Novo Nordisk A/S | 2016-01-04 |
| Investigating the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus (NCT02662114) | Novo Nordisk A/S | 2015-12-08 |
| A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen® (NCT02627287) | Novo Nordisk A/S | 2015-12-01 |
| Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India (NCT02230618) | Novo Nordisk A/S | 2015-11-24 |
| Development of Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes (NCT02617693) | Novo Nordisk A/S | 2015-11-23 |
| A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus. (NCT02607306) | Novo Nordisk A/S | 2015-11-18 |
| A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function (NCT02443155) | Novo Nordisk A/S | 2015-11-10 |
| Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome (NCT02527200) | Novo Nordisk A/S | 2015-11-09 |
| A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes (NCT02612844) | Novo Nordisk A/S | 2015-11-01 |
| Awareness, Care & Treatment in Obesity Management (ACTION) Study (NCT03223493) | Novo Nordisk A/S | 2015-10-29 |
| A Trial to Investigate Different Needle Features Assessed by Comparing Insulin Aspart Pharmacokinetic Profiles (NCT02594033) | Novo Nordisk A/S | 2015-10-27 |
| Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin (NCT02582242) | Novo Nordisk A/S | 2015-10-19 |
| Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes (NCT02568280) | Novo Nordisk A/S | 2015-10-06 |
| A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects (NCT02568306) | Novo Nordisk A/S | 2015-10-05 |
| Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD) (NCT02580032) | Novo Nordisk A/S | 2015-10-05 |
| Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus (NCT02453711) | Novo Nordisk A/S | 2015-10-01 |
| Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes (NCT02461589) | Novo Nordisk A/S | 2015-09-21 |
| Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (NCT02490787) | Novo Nordisk A/S | 2015-09-10 |
| Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S) (NCT02568202) | Novo Nordisk A/S | 2015-09-01 |
| Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly (NCT02557620) | Novo Nordisk A/S | 2015-09-01 |
| Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus (NCT02536859) | Novo Nordisk A/S | 2015-08-31 |
| A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients (NCT02453685) | Novo Nordisk A/S | 2015-08-31 |
| A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus (NCT02420262) | Novo Nordisk A/S | 2015-07-26 |
| A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India (NCT02117622) | Novo Nordisk A/S | 2015-07-24 |
| A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus. (NCT02505334) | Novo Nordisk A/S | 2015-07-21 |
| Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy (NCT02470039) | Novo Nordisk A/S | 2015-06-01 |